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Abstract 
 
Survivin is an Inhibitor of Apoptosis Protein (IAP), which makes it responsible for cell proliferation and survival by 
inhibiting regulated cell death and promoting mitosis. The exact role that it plays in prostate cancer is not yet fully 
understood; expression and regulation of Survivin is the primary focus of my project. The way Survivin was studied 
was through fractionating various cancer cells lines (LaPC-4, PC-3 E+, VCAP, C4-2 and DU145-Spindle, Round 
and Tight) and isolating the nuclear and cytosolic components. These fractionated samples were then treated and 
analyzed using Western Blot analysis being probed for nuclear and cytoplasmic Survivin, respectively. The two main 
goals of my project were to see if there is a difference in expression between nuclear and cytosolic Survivin as 
shown in previous immunohistochemical staining and also to test if movement of the Androgen Receptor from the 
nucleus to the cytoplasm occurs when the cell components are treated with charcoal-stripped media. The found 
results were that there is in fact a difference between nuclear and cytoplasmic Survivin as indicated by band 
definition in Western Blot analysis for all lines used. There was also movement seen in the Androgen Receptor of 
two cells lines (LaPC-4 and C4-2) with charcoal-stripped media. Since little is known about Survivin other than the 
fact that it is most readily seen in cancerous cells in humans, the hope is that through my results we will be able to 
inhibit expression of the protein by understanding what functions the two forms have. 
 
Introduction 
 
Survivin is a protein that functions as a promoter of cell proliferation and survival in tumors and/or 
regularly proliferating cells. The protein counteracts apoptosis by endogenously inhibiting caspases and has been 
found in “almost virtually every human tumor that has been studied”1. Survivin is not usually found in normal adult 
tissues2 but it is seen in large concentrations in more aggressive cancers. Survivin is classified as an Inhibitor of 
Apoptosis Protein, also known as an IAP. Survivin is the smallest known IAP and is approximately 16.5kiloDaltons 
big8. Structurally, it has a single Baculovirus IAP Repeat (BIR) and an extended carboxy-terminal alpha-helical 
coiled-coil, but no RING-finger or other identifiable domain7. The main function of Survivin is to control mitotic 
progression5 and has maximal expression during the G2/M Phase; it is essential for cell division5. However, 
Survivin has rarely, if ever, been studied in prostate cancer.  
An IAP is an Inhibitor of Apoptosis Protein and functions to inhibit regulated cell death. Structurally, IAPs 
consist of 1-3 copies of a 70-amino-acid zinc-finger fold, which is a designated BIR. Certain IAPs can also include a 
caspase-recruitment domain (CARD), and a carboxy-terminal RING finger6. There have been a total of eight 
members of the IAP gene family identified in humans; Survivin is one of them. The most well studied human IAPs 
include:  XIAP, c-IAP1 and c-IAP28.  IAPs work by preventing the processing of initiator caspase-9 from the 
apoptosome, which is responsible for activating effector caspases and death substrates8. 
There are three different identifiable forms of Survivin8. Survivin Wild-type: 3-intron-4-exon structure, 
Survivin-2B: Insertion of an alternative exon 2, and Survivin-∆Ex3: Removal of exon 3 (results in frameshift). As 
well as two different regulation mechanisms; cell cycle dependent and cell cycle independent, respectively. These 
forms are illustrated in Figure 2. 
Cell cycle dependent regulation of Survivin functions at the transcriptional and post-transcriptional level to 
control Survivin expression and involves CDE/CHR G1 repressor elements in the Survivin promoter with increased 
protein stability by phosphorylation on Thr34, respectively8. Cell cycle independent regulation of Survivin functions 
in response to haematopoietic and vascular remodeling cytokines, STAT3-dependent signal transduction and 
phosphatidylinositol 3-kinase activity1. The known pathways for cell-cycle dependence and cell-cycle independence 
are shown in Figure 3. 
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 From previous immunohistochemical (IHC) staining perform by Dr. Knudsen at the Fred Hutchinson 
Cancer Research Center in Seattle, the two distinct functions of Survivin were readily seen in human prostates. 
However, no analyses of Survivin have been previously conducted using human prostate tissue and therefore the 
distinction between cytosolic Survivin (cell-cycle independent) and nuclear Survivin (cell-cycle dependent) must be 
made in order to confirm that two regulatory paths do exist. Analyzing expression of the primary antibodies used in 
the previous IHC experiment must do this. 
 
Methods 
 
The guiding questions behind this study were: Do the antibodies for nuclear and cytosolic Survivin used in 
immunohistochemistry bind to distinct forms of Survivin? As well as: Does treatment of cell lines with charcoal-
stripped media cause the Androgen Receptor to move from the nucleus into the cytoplasm? These two questions are 
important to understanding the function of Survivin in prostate cancer because confirming that there are indeed two 
distinct functions of Survivin and where they are localized in aggressive cancers can help form treatment plans 
according to each individual. Also, confirming that Survivin shows movement during Androgen Ablation shows that 
Survivin, much like the Androgen Receptor will move from a method of proliferation in the nucleus to one of 
survival in the cytoplasm during commonly used prostate cancer treatments. 
In order to test the first hypothesis, LaPC-4, PC-3 E+, VCAP, C4-2 and DU145-Spindle, Round, and Tight 
human cancer cell lines were used. All of the cells were plated from reserves kept in liquid nitrogen and ranging 
from 1980-present. After plating, the cells were kept in the 37oC incubator and fed every other day with passage 
done until there were six plates of each cell line and all plates were the same passage number and dilution. Four 
plates of each cell line were then taken when eighty percent confluent and a fractionation protocol was followed for 
harvesting, while the other two plates were kept as reserves in the incubator and continually fed and passed 
accordingly. 
For fractionation, pre-labeled eppendorf tubes, pre-labeled ultracentrifuge tubes and buffers, reagents, rotor 
of the ultracentrifuge machine, etc. used during the experiment were taken into the cold room (4oC). Twenty-five 
milliliters of Cell Lysis Buffer (Mannitol Lysis Buffer) was made on the day of the experiment from the stock 
solution and placed on ice for thirty minutes before beginning. Three hundred micro liters per plate Cell Lysis Buffer 
(Mannitol Lysis Buffer) w/inhibitors was also prepared the day of the experiment in the cold room and placed on ice 
along with Nuclei Resuspension Buffer and 2X RIPA Buffer with protease and phosphatase inhibitors. 
The four 10-cm plates of cells were taken from the incubator and media was immediately removed by 
suction in the tissue-culture hood. The plates were immediately put on ice and taken to the cold room. In the cold 
room, the plates were washed once with five milliliters of ice-cold PBS/EDTA and subsequently poured off. The 
plates were then washed once with two milliliters of ice cold Cell Lysis Buffer and immediately poured off. The 
plates were placed on ice at a 30o angle to allow the residual liquid to drain before aspirating all the remaining 
liquid. Three hundred micro liters of Cell Lysis Buffer (w/inhibitors) was then added to each plate and laid flat on ice 
for thirty minutes. 
After thirty minutes, the dishes were set at an angle once again on ice. Tilting the dish, the cells were 
scraped with a cell scraper vigorously for 3-4 times, collecting the lysate along the bottom edge of the plate with a 
P1000 pipetteman. Lysates were transferred to pre-chilled eppendorf tubes, pre-labeled as P0 (nuclear fraction) and 
spun at 3000 rpm for ten minutes in the centrifuge. On ice, the supernatant was then transferred to an empty 
eppendorf tube, labeled as P1 and the pellet was kept in P0 tubes. The P0 tubes then had 300 micro liters of Nuclei 
Resuspension Buffer and three micro liters of Dnase I added, combining all tubes. The pellets were Resuspended by 
vortexing until the pellet went into solution. Finally, 200 micro liters of 2X RIPA Buffer (w/inhibitors) was added 
and a nuclear wet mount was prepared to check for appearance of nuclei and little to no debris. 
The P1 eppendorf tubes were then spun at 14000 rpm for twenty minutes. On ice, the supernatant was 
transferred with a 1000 micro liter pipette tip from the P1 tube to a pre-chilled ultracentrifuge tube
After storing and isolating all cell lines, concentration of the protein in the nuclear and cytosolic 
components had to be determined. Doing a Bradford Assay using known dilutions of photosensitive liquid and 
dilutions of either cytosolic or nuclear components from the cell lines did this. Each cell line concentration was 
determined for both components and using a predetermined excel sheet, the necessary amounts of Western Blot 
reagents were added to the protein in either 10, 25, or 50 micro liter dilutions. 
, labeled as P100. 
All supernatants were combined in one ultracentrifuge tube (Beckman Polycarbonate 13x51mm 3mL tubes). After 
completing isolation of the nuclear and cytosolic matter of each cell line, the tubes were stored in the -80oC freezer 
until needed. 
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From this step, Western Blot analysis was then performed using a typical “Western Blot with Wet 
Transfer” protocol and developing using chemiluminescent reagent and radiographic film. 
The Western Blots used to test for differences in cytoplasmic and nuclear Survivin used a mouse 
monoclonal and a rabbit polyclonal primary antibody, respectively. The gels used for both components were 12% 
Bis-Tris with 10 micro liters of ladder loaded and 15 micro liters of protein into each well. The Western Blot was 
run at 200mV for twenty minutes or until a one inch space remained at the bottom of the gel. Transfer was done by 
blocking the gel with a nitrocellulose membrane for 90 minutes at 300mA in the cold room. The membrane was then 
cut and marked to designate the ladder and each component was probed separately. The nuclear fraction was probed 
with milk overnight followed by a second milk-blocking step with secondary antibody in order to reduce 
background noise. The cytoplasmic fraction was probed with a milk overnight primary step followed by a 5% BSA 
blocking step with secondary antibody and was repeated until radiographic films appeared as clear to read as 
possible. These final Western analyses are shown in Figures 4 and 5. 
The second hypothesis was tested by using a similar method as the above mentioned, however, only cell 
lines for LaPC-4 and PC-3 E+ were used. Each cell line was grown using a medium made from charcoal strip in 
order to remove any hormones. The plates were grown for six days and four plates each were obtained from the 
same passage and dilution number. Cells were then harvested using the same method as above for cell fractionation. 
Western Blot analysis for these cells was conducted using the AR 441 primary antibody and an anti-horse secondary 
antibody with milk blocking overnight and 5% BSA blocking on the secondary antibody. The Western Blot for this 
experiment is shown in Figure 6. 
 
Results 
 
 From Western Blot Analysis, I was able to confirm that the antibodies used for nuclear and cytosolic 
Survivin are indeed distinct from each other. When probed for nuclear Survivin, only bands on nuclear fractions are 
visible and are located at approximately 16.5 kDa on the ladder. However, when probed with cytoplasmic Survivin, 
bands are located for nuclear and cytosolic fractions, but at different locations on the molecular weight ladder. It is 
believed that the lower band seen is one of the non-wild type forms of Survivin and the cytosolic fractions at 
approximately 16.5 kDa are the wild type. Further testing must be done in order to confirm these results and identify 
the second visible band in the cytosolic probe. However, a distinction between the two antibodies used is obvious. 
 For the Androgren Receptor, movement of Survivin from the nucleus to the cytoplasm is clearly seen for 
LaPC-4 cells that were treated with androgen ablation and bands appear at the known molecular weight. This is an 
important finding because it shows that Survivin, like the Androgen Receptor can be seen in adult human cancer 
cells as well as the fact that it has two distinct regulations. When androgen is readily available in the nucleus, 
Survivin is able to control mitotic progression in a cell and therefore proliferate. However, when androgen is taken 
away from the host and it moves to the cytoplasm, Survivin goes into a somewhat “dormant” state and moves into 
the cytoplasm as well with the main goal of just “surviving.” The Western Blot for the AR 441 is shown in Figure 6. 
 
Discussion 
 
The findings of this research are extremely important. Since Survivin is known to have a detrimental effect 
in patients with any aggressive cancer, it is important to understand the different regulations and forms that it has. 
Being able to confirm previous results that there are two distinct forms and that the antibodies used to probe for 
them can be used independently are a huge step in furthering our understanding of the protein. Since analysis of 
prostate cancer tissues is currently only able to happen after the patient has died from the disease, this allows us to 
be able to selectively study one form or the other as well as use immunohistochemistry to study which form led to a 
more serious or lethal case of prostate cancer. In doing this, there is the possibility that prostate cancer can be 
controlled better and studied before the demise of the patient.   
Additionally, by studying the movement of the Androgen Receptor from the nucleus to the cytoplasm upon 
androgen ablation, helps to understand the processes and forms that Survivin might take as a result of common 
prostate cancer treatment therapies. If Survivin is moved from a proliferating stage in the nucleus when androgen is 
readily available and then into a “survival” mode when androgen ablation is done, it may appear that the patients’ 
cancer has gone into remission or been cured. This however, is not the case as every human prostate with cancer has 
been seen to have Survivin expression and more so in the nucleus of more aggressive cancer. If Survivin can be 
better regulated or its pathway in the nucleus blocked this can easily be prevented. 
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Overall, there is more work needing to be done on this research, as it is only the beginning of finding a 
possible treatment plan for prostate cancer patients. The above findings need to be confirmed further as well as more 
in-depth biochemical processes of Survivin need to be studied in order to understand all regulations and possible 
inhibitors of the protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Schematic illustrating apoptotic activation of caspases from both extrinsic and intrinsic stimulus. 
Survivin is responsible for inhibiting the intrinsic stimulus and therefore silencing apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Representation of the three forms of Survivin with an alternate exon 2 and removal of exon 3 in 
the non-wild type forms. The removal of exon 3 results in a frameshift mutation of the protein. 
 
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic showing the two ways Survivin functions: either in a cell-cycle dependent manner, or 
in a cell-cycle independent manner, which leads to activating of cytokines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Western Blot probing for nuclear Survivin.  Distinct bands are seen only in fractions of nuclear 
cells for all cell lines at the expected 16.5 kDa molecular weight.  Order of loading: P0-S, C+M-S, P0-R, C+M-R, 
P0-T, C+M-T, P0 LaPC4, C+M LaPC4, P0 PC3, C+M PC3, P0 C4-2, C+M C42, P0-VCAP, C+M-VCAP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Western Blot probing for cytoplasmic Survivin.  Distinct bands are seen for all fractions at the 
expected molecular weight with lower bands being seen below 16.5 kDa, believed to be a mutation in the Survivin 
protein.  Order of loading: P0-S, C+M-S, P0-R, C+M-R, P0-T, C+M-T, P0 LaPC4, C+M LaPC4, P0 PC3, C+M 
PC3, P0 C4-2, C+M C42, P0-VCAP, C+M-VCAP. 
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Figure 6.  From left to right: Ladder indicating molecular weight in kDa, Nuclear fraction without androgen 
ablation, Cytosolic fraction without androgen ablation, Nuclear fraction with androgen ablation, Cytosolic fraction 
with androgen ablation, Positive LnCAP control.  When androgen is available to cells, bands are seen in the nuclear 
and cytosolic fractions of LaPC-4 cells, however when androgen has been stripped from the cells, only a band is 
seen in the cytoplasm.  The large band seen to the far right is a control for the AR 441 primary antibody. 
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